News

Discover REGENXBIO's Upcoming Investor Engagements and Vision

Discover REGENXBIO's Upcoming Investor Engagements and Vision

REGENXBIO's Participation in Notable Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX) has shared exciting news regarding its involvement in a series of prominent investor conferences. These events provide a vital platform for the company to showcase its pioneering advancements in gene therapy and to engage with stakeholders in the biotechnology community.

Upcoming Events and Conferences

Chardan's 9th Annual Genetic Medicines Conference

REGENXBIO plans to take part in Chardan's inaugural genetic medicines conference. This event is scheduled for October 21, where representatives will contribute to comprehensive discussions surrounding gene therapies and their implications in current medical treatments. Two significant panels are included in the agenda:

  • "Battleground States for Muscular Dystrophies" at 2:00 p.m. ET.
  • "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers" at 2:45 p.m. ET.

This is a fantastic opportunity for REGENXBIO to engage with other leaders in the industry and discuss ongoing innovations in muscular dystrophy treatment.

Guggenheim Securities Annual Healthcare Innovation Conference

Following this, on November 10, REGENXBIO will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Here, the company will engage in a fireside chat that focuses on the evolving landscape of healthcare innovation, starting at 9:00 a.m. ET.

Stifel 2025 Healthcare Conference

Furthermore, on November 11, REGENXBIO will also feature in the Stifel 2025 Healthcare Conference with another fireside chat at 1:20 p.m. ET. This engagement aims to give insights into REGENXBIO's revolutionary gene therapies and the impact they hold for patients.

Webcast Accessibility and Archiving

For those interested in tuning into these insightful events, live webcasts will be made available on REGENXBIO's Investors section of their website. You can catch the majority of these discussions live, with access to archived replays for about 30 days after the events, allowing for convenient viewing opportunities.

About REGENXBIO Inc.

REGENXBIO has been at the forefront of biotechnology since its establishment in 2009, focusing on leveraging the potential of gene therapy to bring transformative solutions to healthcare challenges. With a robust late-stage pipeline, the company is committed to developing one-time treatments for rare diseases and retinal disorders.

Among its promising therapies are:

  • RGX-202 for Duchenne Muscular Dystrophy
  • Clemidsogene lanparvovec (RGX-121) for MPS II
  • RGX-111 for MPS I, in collaboration with partners such as Nippon Shinyaku
  • Surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy, developed in collaboration with AbbVie

Thousands of patients have already benefited from REGENXBIO's AAV platform, reinforcing the need for innovative therapies like ZOLGENSMA from Novartis. The future looks promising as REGENXBIO continues to develop gene therapies that could redefine healthcare delivery for millions.

Contacts

Dana Cormack
Corporate Communications

Investors:
George E. MacDougall
Investor Relations

Frequently Asked Questions

What is REGENXBIO known for?

REGENXBIO is a biotechnology company focused on advancing gene therapy to treat various diseases, using their proprietary AAV platform.

When will REGENXBIO participate in the conferences?

REGENXBIO is set to participate in conferences on October 21, November 10, and November 11, 2025.

How can I access the webcasts of these events?

Live webcasts can be accessed in the Investors section of REGENXBIO's website, with replays available for around 30 days after the events.

What treatments does REGENXBIO offer?

The company offers several gene therapies, including treatments for Duchenne Muscular Dystrophy and mucopolysaccharidoses, among others.

What is the mission of REGENXBIO?

REGENXBIO’s mission is to transform lives through the curative potential of gene therapy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 15

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

ANI Pharmaceuticals Plans to Shine at Biotech Conference

Updated Category News Views 257

ANI Pharmaceuticals Set for Key Presentation at Biotech Conference ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is gearing up to showcase its advancements at the Guggenheim Biotech Conference. On an exciting date, Nikhil Lalwani, the Company’s President and CEO, along with Stephen Carey, the CFO, will host a fireside chat to discuss the latest developments and future plans...

Continue Reading
New Shuttle Drives Economic Recovery on O'ahu

Updated Category News Views 26

Reviving the North Shore Economy, One Shuttle Ride at a Time Not every day do you see a $5 investment with such community punch. On June 29, a new bus service launches, whisking folks from Waik?k? and Ko Olina to O?ahu’s North Shore. But this ain't just another tourist bus ride—it's a lifeline for local businesses hit hard by March's kona low storms. Connecting...

Continue Reading
Virginia Cancer Specialists Expands Services with New Center

Updated Category News Views 21

Virginia Cancer Specialists Expands its Reach with a New Center Virginia Cancer Specialists, a leading private cancer practice in the region, has announced the opening of their newly expanded cancer center. This important development aims to enhance patient care and provide access to the latest cancer treatments. The expansion not only signifies growth but also a...

Continue Reading
Key Financial Dates for TCM Group A/S's Upcoming Year

Updated Category News Views 167

Important Financial Calendar for TCM Group A/S TCM Group A/S is a significant player in the kitchen and furniture manufacturing industry. As the year approaches its end, the company has established key dates for reporting and annual meetings, signaling to shareholders and stakeholders the importance of staying informed. Scheduled Report Releases and Meetings The Board of...

Continue Reading
Unexpected Chicago PMI Falls Raises Concerns for Manufacturing

Updated Category News Views 323

Understanding the Recent Chicago PMI Decline Recently, the Chicago Purchasing Managers' Index (PMI) reported a surprising score of 36.9, highlighting ongoing challenges in the manufacturing sector within the region. This score is a clear indication that the manufacturing landscape in Chicago is experiencing significant contraction, a worrisome sign for the local and...

Continue Reading